# Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

> **NCT02484404** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 268 (actual)

## Conditions studied

- Colorectal Neoplasms
- Breast Neoplasms

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Cediranib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02484404
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06-29
- **Primary completion:** 2027-10-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484404, "Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02484404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*